Minoryx Therapeutics S.L.
2 products tracked · names used in filings: Minoryx Therapeutics S.L.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Mon 21 Sep 2026🇪🇺 EU approval (EC decision)
Nezglyal (leriglitazone) approved in the EU
Marketing authorisation to Minoryx Therapeutics S.L.; Orphan, Exceptional circumstances, Additional monitoring · source
Thu 23 Jul 2026🇪🇺 CHMP positive opinion
Nezglyal (leriglitazone): CHMP positive opinion
Minoryx Therapeutics S.L.; Orphan, Exceptional circumstances, Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Nezglyal leriglitazone | Refused | |
| 🇪🇺 | Nezglyal leriglitazone | Authorised | 2026-09-21 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.